Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA vs FLOMAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Hypertension,Benign prostatic hyperplasia
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Off-label: adjunctive therapy for ureteral calculi expulsion
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Extensively metabolized in the liver via CYP3A4 and CYP2D6 enzymes.
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
98-99% bound to plasma proteins (primarily albumin).
94-99% bound primarily to alpha-1 acid glycoprotein, with high affinity.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Approximately 16 L/kg (or 16 L for an average 70 kg patient), indicating extensive tissue distribution.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
Oral bioavailability is approximately 90% (capsule) due to extensive absorption, with minimal first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
No adjustment required for GFR ≥10 m L/min; insufficient data for GFR <10 m L/min, use with caution.
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; consider starting at 0.4 mg once daily. Child-Pugh Class C: Contraindicated.
Safety and efficacy not established in pediatric patients; use not recommended.
Not approved for pediatric use; safety and efficacy not established.
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
Same dosing as adults; monitor for orthostatic hypotension and dizziness. Consider starting at 0.4 mg once daily.
None
None.
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Orthostatic hypotension and syncope, especially upon initiation or dose increase,Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Hepatic impairment,Consideration of prostate cancer before initiating therapy
Hypersensitivity to doxazosin or other quinazolines
Hypersensitivity to tamsulosin hydrochloride or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients with moderate to severe hepatic impairment
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Grapefruit juice may increase tamsulosin levels; avoid concurrent intake. High-fat meals can decrease absorption; administer 30 minutes after the same meal daily.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 30 times the human exposure). There are no adequate and well-controlled studies in pregnant women; use only if clearly needed. First trimester: no known increased risk of major malformations. Second/third trimester: no known specific fetal risks; however, alpha-blockers may cause hypotension in the mother, potentially affecting placental perfusion. No reports of teratogenic effects in humans.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
Tamsulosin is excreted in rat milk at concentrations 20-fold higher than maternal plasma. No human data exist; M/P ratio is not established. Due to potential for adverse effects (e.g., hypotension) in the nursing infant, breastfeeding is generally not recommended. Discontinue drug or bottle-feed, considering importance of therapy to mother.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
No specific pharmacokinetic studies during pregnancy. Dose adjustments are not routinely recommended; however, hypotension risk may be increased due to pregnancy-related hemodynamic changes. Use the lowest effective dose and monitor for maternal hypotension to avoid fetal compromise.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
First-dose orthostatic hypotension is common; administer at bedtime. Avoid use in patients with history of cataract surgery due to intraoperative floppy iris syndrome (IFIS). Tamsulosin is not recommended for hypertension. Renal impairment does not require dose adjustment. Use caution with strong CYP3A4 inhibitors (e.g., ketoconazole) and PDE5 inhibitors (e.g., sildenafil) due to enhanced hypotensive effects.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
Take this medication approximately 30 minutes after the same meal each day to maintain consistent absorption.,Avoid getting up too quickly from a sitting or lying position to minimize dizziness.,Inform your ophthalmologist about tamsulosin use before any cataract surgery due to risk of floppy iris syndrome.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you miss a dose, skip it and take the next dose at the usual time; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA vs FLOMAX, answered by our medical review team.
CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. FLOMAX is a Alpha-1 Blocker that works by Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA and FLOMAX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. The standard adult dose of FLOMAX is: 0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA and FLOMAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. FLOMAX is classified as Category C. Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 3. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.